Accord Healthcare, a generic pharmaceutical company, has added Pirfenidone to its oral solid products portfolio. The new drug is therapeutically equivalent to Genentech's Esbriet and approved to treat idiopathic pulmonary fibrosis (IPF), a lung disease that involves scarring of the lungs with an unknown cause. The new product, offered in 267 mg and 801 mg tablets, is currently available to ship.
Idiopathic Pulmonary Fibrosis is a lung disease that generally affects older adults and occurs when lung tissue becomes damaged and scarred. The permanent scarring in the lungs is called fibrosis. IPF affects roughly 13 to 20 per 100,000 people worldwide. About 100,000 people are affected in the U.S., and 30-40,000 new cases are diagnosed a year.
Pirfenidone may cause nausea, diarrhea, heartburn, or dizziness in some patients. Other side effects can be serious, though may be reduced with a dosage adjustment. Further information about safety and potential side effects can be found on our website.
Esbriet was approved by the FDA in 2017 for the treatment of Idiopathic Pulmonary Fibrosis. For more information, please visit the Products page at Accord Healthcare US.